Guzip Biomarkers Corporation spun out from Taipei Medical University in Aug 7, 2018, carries a vision for clinical applications of novel DNA methylation biomarkers. Guzip is dedicated to improve women’s health with personalized medicine, and the MPap® DNA Methylation Detection Kit as company’s first IVD test is intended to verify the risk of endometrial cancer prior to an invasive endometrial diagnostic procedure (IVP) assuring the necessity of an IVP.